Because cancer patients are individuals

Mission

The mission of 2cureX is to improve cancer treatment with the individual patient in focus.

By testing the patient’s cancer cells for their sensitivity against standard and experimental anti-cancer drugs, IndiTreat™ assists the oncologist in selecting the most effective treatment for the individual patient.

Matching of the patient with the right medical treatment is of paramount importance for efficient combat of any cancer

News and Press Releases

2018-05-24

Press releases regulatory

The University Hospital, Rigshospitalet (Copenhagen), University Medical Center Hamburg-Eppendorf (Hamburg) and 2cureX have initiated a clinical study in ovarian cancer

Rigshospitalet (“RH”), University Medical Center Hamburg-Eppendorf, Hamburg (“UKE”) and 2cureX AB (“2cureX”) today announce that they have initiated a clinical...

2018-05-18

Press releases regulatory

2cureX AB publishes interim report for the first financial quarter of 2018

2cureX AB (”2cureX”) hereby publishes the interim report for the first financial quarter of 2018. The interim report is available...

2018-05-07

Press releases regulatory

2cureX AB publishes annual report for the fiscal year 2017

The board and the Chief Executive Officer of 2cureX AB (”2cureX”) hereby publishes the annual report for the fiscal year...

To the news archive

Contact information

Laboratory: 2cureX, Building 8, 2. Tværvej, Bispebjerg Bakke 23, 2400 Copenhagen NV, Denmark| Phone: +45 2211 5399| E-mail: info@2curex.com